Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 20
HOS-086303 · Präparat HOS-083284
HMG Co-A Reductase
Inhibitors
Atorvastatin, Fluvastatin, Lovastatin, HMG-CoA reductase inhibitors which are highly dependent on CYP3A metabolism,
Pravastatin, Rosuvastatin, Simvastatin such as lovastatin and simvastatin, are expected to have markedly increased plasma
concentrations when co-administered with ritonavir dosed as an antiretroviral agent
or as a pharmacokinetic enhancer. Since increased concentrations of lovastatin and
simvastatin may predispose patients to myopathies, including rhabdomyolysis, the
combination of these medicinal products with ritonavir is contraindicated (see
section 4.3). Atorvastatin is less dependent on CYP3A for metabolism. While
rosuvastatin elimination is not dependent on CYP3A, an elevation of rosuvastatin
exposure has been reported with ritonavir co-administration. The mechanism of this
interaction is not clear, but may be the result of transporter inhibition. When used
with ritonavir dosed as a pharmacokinetic enhancer or as an antiretroviral agent, the
lowest possible doses of atorvastatin or rosuvastatin should be administered. The
metabolism of pravastatin and fluvastatin is not dependent on CYP3A, and
interactions are not expected with ritonavir. If treatment with an HMG-CoA
reductase inhibitor is indicated, pravastatin or fluvastatin is recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lovastatin (HOS-086157) atorvastatin (HOS-086304) simvastatin (HOS-086158) rosuvastatin (HOS-086307) fluvastatin (HOS-086305) pravastatin (HOS-086306)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 9aca472a9605d2ce92f2e3c73c3d58774cec61e0cad5a2ae7e9aa807365f0d07 · Zeichen 43147–44996 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 52
HOS-086472 · Präparat HOS-083284
HMG Co-A Reductase
Inhibitors
Atorvastatin, Fluvastatin, Lovastatin, HMG-CoA reductase inhibitors which are highly dependent on CYP3A metabolism, such
Pravstatin, Rosuvastatin, Simvastatin as lovastatin and simvastatin, are expected to have markedly increased plasma
concentrations when co-administered with ritonavir dosed as an antiretroviral agent or as
a pharmacokinetic enhancer. Since increased concentrations of lovastatin and simvastatin
may predispose patients to myopathies, including rhabdomyolysis, the combination of
these medicinal products with ritonavir is contraindicated (see section 4.3). Atorvastatin
is less dependent on CYP3A for metabolism. While rosuvastatin elimination is not
dependent on CYP3A, an elevation of rosuvastatin exposure has been reported with
ritonavir co-administration. The mechanism of this interaction is not clear, but may be
the result of transporter inhibition. When used with ritonavir dosed as a pharmacokinetic
enhancer or as an antiretroviral agent, the lowest possible doses of atorvastatin or
rosuvastatin should be administered. The metabolism of pravastatin and fluvastatin is not
dependent on CYP3A, and interactions are not expected with ritonavir. If treatment with
an HMG-CoA reductase inhibitor is indicated, pravastatin or fluvastatin is recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lovastatin (HOS-086157) atorvastatin (HOS-086304) simvastatin (HOS-086158) rosuvastatin (HOS-086307) fluvastatin (HOS-086305) pravastatin (HOS-086306)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage aecf6db95f104726bea3f53130826841fcecb464a1fff5ff24afdad33e090079 · Zeichen 44359–46167 im Abschnitt
Wechselwirkungen · Xenical
Xenical 120 mg hard capsules · Abschnitt 4.5 · PDF-Seite 4
HOS-087481 · Präparat HOS-083511
Lack of interactions
No interactions with amitriptyline, atorvastatin, biguanides, digoxin, fibrates, fluoxetine, losartan,
phenytoin, phentermine, pravastatin, nifedipine Gastrointestinal Therapeutic System (GITS),
nifedipine slow release, sibutramine or alcohol have been observed. The absence of these interactions
has been demonstrated in specific drug-drug-interaction studies.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nifedipine (HOS-086289) losartan (HOS-087482) amitriptyline (HOS-085911) atorvastatin (HOS-086304) digoxin (HOS-086172) phentermine (HOS-087483) sibutramine (HOS-087484) fluoxetine (HOS-085946) phenytoin (HOS-084531) pravastatin (HOS-086306)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-05-10T13:00:00Z · SHA-256 632b9f6a72b3014c31eea28c23202ae6368254ac0e6429088389d3ea57a05739 · Passage 238caf08ee6a247653110f4663196875c65d11dc61039cdb333f880c45aa71f3 · Zeichen 2976–3358 im Abschnitt
Wechselwirkungen · Arava
Arava 10 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9
HOS-089672 · Präparat HOS-083907
Effect on BCRP (Breast Cancer Resistance Protein) and /or organic anion transporting polypeptide
B1 and B3 (OATP1B1/B3) substrates
There was an increase in mean rosuvastatin Cmax and AUC (2.65- and 2.51-fold, respectively),
following repeated doses of A771726. However, there was no apparent impact of this increase in
plasma rosuvastatin exposure on the HMG-CoA reductase activity. If used together, the dose of
rosuvastatin should not exceed 10 mg once daily. For other substrates of BCRP (e.g., methotrexate,
topotecan, sulfasalazine, daunorubicin, doxorubicin) and the OATP family especially HMG-CoA
reductase inhibitors (e.g., simvastatin, atorvastatin, pravastatin, methotrexate, nateglinide,
repaglinide, rifampicin) concomitant administration should also be undertaken with caution. Patients
should be closely monitored for signs and symptoms of excessive exposure to the medicinal
products and reduction of the dose of these medicinal products should be considered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): daunorubicin (HOS-089674) sulfasalazine (HOS-089673) atorvastatin (HOS-086304) simvastatin (HOS-086158) rosuvastatin (HOS-086307) nateglinide (HOS-089675) topotecan (HOS-086047) doxorubicin (HOS-084538) repaglinide (HOS-086935) pravastatin (HOS-086306) methotrexate (HOS-087522)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-07T09:36:00Z · SHA-256 cd6bb826d7f71e10dd6cea956a4c1d40ef339b9461b69d87c77735d5508df2d9 · Passage f37465d9d3fa779177b38c1116c6d5221ab029de8d593b9e1a786c9960c38e00 · Zeichen 5491–6465 im Abschnitt
Wechselwirkungen · Arava
Arava 20 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 26
HOS-089736 · Präparat HOS-083907
Effect on BCRP (Breast Cancer Resistance Protein) and /or organic anion transporting polypeptide
B1 and B3 (OATP1B1/B3) substrates
There was an increase in mean rosuvastatin Cmax and AUC (2.65- and 2.51-fold, respectively),
following repeated doses of A771726. However, there was no apparent impact of this increase in
plasma rosuvastatin exposure on the HMG-CoA reductase activity. If used together, the dose of
rosuvastatin should not exceed 10 mg once daily. For other substrates of BCRP (e.g., methotrexate,
topotecan, sulfasalazine, daunorubicin, doxorubicin) and the OATP family especially HMG-CoA
reductase inhibitors (e.g., simvastatin, atorvastatin, pravastatin, methotrexate, nateglinide,
repaglinide, rifampicin) concomitant administration should also be undertaken with caution. Patients
should be closely monitored for signs and symptoms of excessive exposure to the medicinal
products and reduction of the dose of these medicinal products should be considered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): daunorubicin (HOS-089674) sulfasalazine (HOS-089673) atorvastatin (HOS-086304) simvastatin (HOS-086158) rosuvastatin (HOS-086307) nateglinide (HOS-089675) topotecan (HOS-086047) doxorubicin (HOS-084538) repaglinide (HOS-086935) pravastatin (HOS-086306) methotrexate (HOS-087522)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-07T09:36:00Z · SHA-256 cd6bb826d7f71e10dd6cea956a4c1d40ef339b9461b69d87c77735d5508df2d9 · Passage f37465d9d3fa779177b38c1116c6d5221ab029de8d593b9e1a786c9960c38e00 · Zeichen 5493–6467 im Abschnitt
Wechselwirkungen · Arava
Arava 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 43
HOS-089796 · Präparat HOS-083907
Effect on BCRP (Breast Cancer Resistance Protein) and /or organic anion transporting polypeptide
B1 and B3 (OATP1B1/B3) substrates
There was an increase in mean rosuvastatin Cmax and AUC (2.65- and 2.51-fold, respectively),
following repeated doses of A771726. However, there was no apparent impact of this increase in
plasma rosuvastatin exposure on the HMG-CoA reductase activity. If used together, the dose of
rosuvastatin should not exceed 10 mg once daily. For other substrates of BCRP (e.g., methotrexate,
topotecan, sulfasalazine, daunorubicin, doxorubicin) and the OATP family especially HMG-CoA
reductase inhibitors (e.g., simvastatin, atorvastatin, pravastatin, methotrexate, nateglinide,
repaglinide, rifampicin) concomitant administration should also be undertaken with caution. Patients
should be closely monitored for signs and symptoms of excessive exposure to the medicinal
products and reduction of the dose of these medicinal products should be considered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): daunorubicin (HOS-089674) sulfasalazine (HOS-089673) atorvastatin (HOS-086304) simvastatin (HOS-086158) rosuvastatin (HOS-086307) nateglinide (HOS-089675) topotecan (HOS-086047) doxorubicin (HOS-084538) repaglinide (HOS-086935) pravastatin (HOS-086306) methotrexate (HOS-087522)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-07T09:36:00Z · SHA-256 cd6bb826d7f71e10dd6cea956a4c1d40ef339b9461b69d87c77735d5508df2d9 · Passage f37465d9d3fa779177b38c1116c6d5221ab029de8d593b9e1a786c9960c38e00 · Zeichen 5489–6463 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.5 · PDF-Seite 24–25
HOS-108934 · Präparat HOS-093083
24
of lomitapide are expected to
increase.
Atorvastatin Atorvastatin: The combination of Kaletra with
AUC: ↑ 5.9-fold atorvastatin is not recommended.
Cmax: ↑ 4.7-fold If the use of atorvastatin is
Due to CYP3A inhibition by considered strictly necessary, the
lopinavir/ritonavir. lowest possible dose of
atorvastatin should be
administered with careful safety
monitoring (see section 4.4).
Rosuvastatin, 20 mg QD Rosuvastatin: Caution should be exercised and
AUC: ↑ 2-fold reduced doses should be
Cmax: ↑ 5-fold considered when Kaletra is
While rosuvastatin is poorly co-administered with rosuvastatin
metabolised by CYP3A4, an (see section 4.4).
increase of its plasma
concentrations was observed.
The mechanism of this interaction
may result from inhibition of
transport proteins.
Fluvastatin or Pravastatin Fluvastatin, Pravastatin: If treatment with an HMG-CoA
No clinical relevant interaction reductase inhibitor is indicated,
expected. fluvastatin or pravastatin is
Pravastatin is not metabolised by recommended.
CYP450.
Fluvastatin is partially
metabolised by CYP2C9.
Opioids
Buprenorphine, 16 mg QD Buprenorphine: ↔ No dose adjustment necessary.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atorvastatin (HOS-086304) lomitapide (HOS-086160) rosuvastatin (HOS-086307) fluvastatin (HOS-086305) buprenorphine (HOS-086193) pravastatin (HOS-086306)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 2a27011337575de5ab6a9cbb05a4ed667b9b72fba13fff3beebbce86283b037b · Zeichen 57600–59815 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 59–60
HOS-109022 · Präparat HOS-093083
59
Herbal products
St John’s wort Lopinavir: Herbal preparations containing St
(Hypericum perforatum) Concentrations may be reduced John’s wort must not be combined
due to induction of CYP3A by the with lopinavir and ritonavir. If a
herbal preparation St John’s wort. patient is already taking St John’s
wort, stop St John’s wort and if
possible check viral levels. Lopinavir
and ritonavir levels may increase on
stopping St John’s wort. The dose of
Kaletra may need adjusting. The
inducing effect may persist for at
least 2 weeks after cessation of
treatment with St John’s wort (see
section 4.3). Therefore, Kaletra can
be started safely 2 weeks after
cessation of St John's wort.
Immunosuppressants
Cyclosporin, Sirolimus Cyclosporin, Sirolimus More frequent therapeutic
(rapamycin), and (rapamycin), Tacrolimus: concentration monitoring is
Tacrolimus Concentrations may be increased recommended until plasma levels of
due to CYP3A inhibition by these products have been stabilised.
lopinavir/ritonavir.
Lipid lowering agents
Lovastatin and Lovastatin, Simvastatin: Since increased concentrations of
Simvastatin Markedly increased plasma HMG-CoA reductase inhibitors may
concentrations due to CYP3A cause myopathy, including
inhibition by lopinavir/ritonavir. rhabdomyolysis, the combination of
these agents with Kaletra is
contraindicated (see section 4.3).
Lipid-modifying agents
Lomitapide CYP3A4 inhibitors increase the Concomitant use of Kaletra with
exposure of lomitapide, with lomitapide is contraindicated (see
strong inhibitors increasing prescribing information for
exposure approximately 27-fold. lomitapide) (see section 4.3).
Due to CYP3A inhibition by
lopinavir/ritonavir, concentrations
of lomitapide are expected to
increase.
Atorvastatin Atorvastatin: The combination of Kaletra with
AUC: ↑ 5.9-fold atorvastatin is not recommended. If
Cmax: ↑ 4.7-fold the use of atorvastatin is considered
Due to CYP3A inhibition by strictly necessary, the lowest possible
lopinavir/ritonavir. dose of atorvastatin should be
administered with careful safety
monitoring (see section 4.4).
Rosuvastatin, 20 mg QD Rosuvastatin: Caution should be exercised and
AUC: ↑ 2-fold reduced doses should be considered
Cmax: ↑ 5-fold when Kaletra is co-administered with
While rosuvastatin is poorly rosuvastatin (see section 4.4).
metabolised by CYP3A4, an
increase of its plasma
concentrations was observed. The
mechanism of this interaction may
result from inhibition of transport
proteins.
Fluvastatin or Fluvastatin, Pravastatin: If treatment with an HMG-CoA
Pravastatin reductase inhibitor is indicated,
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lovastatin (HOS-086157) atorvastatin (HOS-086304) lomitapide (HOS-086160) simvastatin (HOS-086158) rosuvastatin (HOS-086307) fluvastatin (HOS-086305) tacrolimus (HOS-085202) sirolimus (HOS-085172) pravastatin (HOS-086306)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 828eb1430737116e7e38afe94ac9495cef2e1489ddb625df82544aac21c48455 · Zeichen 52305–56991 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 60–61
HOS-109023 · Präparat HOS-093083
60
No clinical relevant interaction fluvastatin or pravastatin is
expected. recommended.
Pravastatin is not metabolised by
CYP450.
Fluvastatin is partially
metabolised by CYP2C9.
Opioids
Buprenorphine, 16 mg Buprenorphine: ↔ No dose adjustment necessary.
QD
Methadone Methadone: ↓ Monitoring plasma concentrations of
methadone is recommended.
Oral contraceptives
Ethinyl Oestradiol Ethinyl Oestradiol: ↓ In case of co-administration of
Kaletra with contraceptives
containing ethinyl oestradiol
(whatever the contraceptive
formulation e.g. oral or patch),
additional methods of contraception
must be used.
Smoking cessation aids
Bupropion Buproprion and its active If the co-administration of Kaletra
metabolite, hydroxybupropion: with bupropion is judged
AUC and Cmax ↓ ~50% unavoidable, this should be done
under close clinical monitoring for
This effect may be due to bupropion efficacy, without
induction of bupropion exceeding the recommended dosage,
metabolism. despite the observed induction.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): bupropion (HOS-086329) methadone (HOS-086198) fluvastatin (HOS-086305) buprenorphine (HOS-086193) pravastatin (HOS-086306)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 66795734d42d6453cc3ecae53ffe464f62e190070894ffc9d2f185474a98d737 · Zeichen 57035–59066 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 95–96
HOS-109101 · Präparat HOS-093083
95
Immunosuppressants
Cyclosporin, Sirolimus Cyclosporin, Sirolimus More frequent therapeutic
(rapamycin), and (rapamycin), Tacrolimus: concentration monitoring is
Tacrolimus Concentrations may be increased recommended until plasma levels of
due to CYP3A inhibition by these products have been stabilised.
lopinavir/ritonavir.
Lipid lowering agents
Lovastatin and Lovastatin, Simvastatin: Since increased concentrations of
Simvastatin Markedly increased plasma HMG-CoA reductase inhibitors
concentrations due to CYP3A may cause myopathy, including
inhibition by lopinavir/ritonavir. rhabdomyolysis, the combination of
these agents with Kaletra is
contraindicated (see section 4.3).
Lipid-modifying agents
Lomitapide CYP3A4 inhibitors increase the Concomitant use of Kaletra with
exposure of lomitapide, with lomitapide is contraindicated (see
strong inhibitors increasing prescribing information for
exposure approximately 27-fold. lomitapide) (see section 4.3).
Due to CYP3A inhibition by
lopinavir/ritonavir, concentrations
of lomitapide are expected to
increase.
Atorvastatin Atorvastatin: The combination of Kaletra with
AUC: ↑ 5.9-fold atorvastatin is not recommended. If
Cmax: ↑ 4.7-fold the use of atorvastatin is considered
Due to CYP3A inhibition by strictly necessary, the lowest
lopinavir/ritonavir. possible dose of atorvastatin should
be administered with careful safety
monitoring (see section 4.4).
Rosuvastatin, 20 mg QD Rosuvastatin: Caution should be exercised and
AUC: ↑ 2-fold reduced doses should be considered
Cmax: ↑ 5-fold when Kaletra is co-administered
While rosuvastatin is poorly with rosuvastatin (see section 4.4).
metabolised by CYP3A4, an
increase of its plasma
concentrations was observed. The
mechanism of this interaction may
result from inhibition of transport
proteins.
Fluvastatin or Fluvastatin, Pravastatin: If treatment with an HMG-CoA
Pravastatin No clinical relevant interaction reductase inhibitor is indicated,
expected. fluvastatin or pravastatin is
Pravastatin is not metabolised by recommended.
CYP450.
Fluvastatin is partially
metabolised by CYP2C9.
Opioids
Buprenorphine, 16 mg Buprenorphine: ↔ No dose adjustment necessary.
QD
Methadone Methadone: ↓ Monitoring plasma concentrations
of methadone is recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): methadone (HOS-086198) lovastatin (HOS-086157) atorvastatin (HOS-086304) lomitapide (HOS-086160) simvastatin (HOS-086158) rosuvastatin (HOS-086307) fluvastatin (HOS-086305) buprenorphine (HOS-086193) tacrolimus (HOS-085202) sirolimus (HOS-085172) pravastatin (HOS-086306)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 8615aceaaf9aeead58e7d8428a116c5869ad8f9e57e471dff2f6359133eeb12b · Zeichen 55116–58920 im Abschnitt
Wechselwirkungen · Reyataz
REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 23
HOS-112115 · Präparat HOS-093615
The increase in progestin exposure may
lead to related side effects (e.g., insulin
resistance, dyslipidemia, acne and
spotting), thus possibly affecting the
compliance.
LIPID-MODIFYING AGENTS
HMG-CoA reductase inhibitors
Simvastatin Simvastatin and lovastatin are highly Co-administration of simvastatin or
Lovastatin dependent on CYP3A4 for their lovastatin with REYATAZ is
metabolism and co-administration with contraindicated due to an increased
REYATAZ may result in increased risk of myopathy including
concentrations. rhabdomyolysis (see section 4.3).
Atorvastatin The risk of myopathy including Co-administration of atorvastatin
rhabdomyolysis may also be increased with REYATAZ is not
with atorvastatin, which is also recommended. If the use of
metabolised by CYP3A4. atorvastatin is considered strictly
necessary, the lowest possible dose
of atorvastatin should be
administered with careful safety
monitoring (see section 4.4).
Pravastatin Although not studied, there is a potential Caution should be exercised.
Fluvastatin for an increase in pravastatin or fluvastatin
exposure when co-administered with
protease inhibitors. Pravastatin is not
metabolised by CYP3A4. Fluvastatin is
partially metabolised by CYP2C9.
Other lipid-modifying agents
Lomitapide Lomitapide is highly dependent on Co-administration of lomitapide
CYP3A4 for metabolism and co- and REYATAZ with ritonavir is
administration with REYATAZ with contraindicated due to a potential
ritonavir may result in increased risk of markedly increased
concentrations. transaminase levels and
hepatotoxicity (see section 4.3).
INHALED BETA AGONISTS
Salmeterol Co-administration with REYATAZ may Co-administration of salmeterol
result in increased concentrations of with REYATAZ is not
salmeterol and an increase in salmeterol- recommended (see section 4.4).
associated adverse events.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): protease (HOS-085623) lovastatin (HOS-086157) atorvastatin (HOS-086304) lomitapide (HOS-086160) simvastatin (HOS-086158) fluvastatin (HOS-086305) salmeterol (HOS-086285) lead (HOS-085592) ritonavir (HOS-084521) pravastatin (HOS-086306)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage 8b78bbc3e02ae5f0c1ee3136e8833b5a4db25ba5d80192d381b81c04949c1b1f · Zeichen 66846–70225 im Abschnitt
Wechselwirkungen · Reyataz
REYATAZ 50 mg oral powder · Abschnitt 4.5 · PDF-Seite 59
HOS-112201 · Präparat HOS-093615
The increase in progestin exposure may
lead to related side effects (e.g., insulin
resistance, dyslipidemia, acne and
spotting), thus possibly affecting the
compliance.
LIPID-MODIFYING AGENTS
HMG-CoA reductase inhibitors
Simvastatin Simvastatin and lovastatin are highly Co-administration of
Lovastatin dependent on CYP3A4 for their simvastatin or lovastatin with
metabolism and co-administration with REYATAZ is contraindicated
REYATAZ may result in increased due to an increased risk of
concentrations. myopathy including
rhabdomyolysis (see
section 4.3).
Atorvastatin The risk of myopathy including Co-administration of
rhabdomyolysis may also be increased with atorvastatin with REYATAZ is
atorvastatin, which is also metabolised by not recommended. If the use of
CYP3A4. atorvastatin is considered
strictly necessary, the lowest
possible dose of atorvastatin
should be administered with
careful safety monitoring (see
section 4.4).
Pravastatin Although not studied, there is a potential Caution should be exercised.
Fluvastatin for an increase in pravastatin or fluvastatin
exposure when co-administered with
protease inhibitors. Pravastatin is not
metabolised by CYP3A4. Fluvastatin is
partially metabolised by CYP2C9.
Other lipid-modifying agents
Lomitapide Lomitapide is highly dependent on Co-administration of
CYP3A4 for metabolism and co- lomitapide and REYATAZ
administration with REYATAZ with with ritonavir is
ritonavir may result in increased contraindicated due to a
concentrations. potential risk of markedly
increased transaminase levels
and hepatotoxicity (see
section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): protease (HOS-085623) lovastatin (HOS-086157) atorvastatin (HOS-086304) lomitapide (HOS-086160) simvastatin (HOS-086158) fluvastatin (HOS-086305) lead (HOS-085592) ritonavir (HOS-084521) pravastatin (HOS-086306)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage 44aa56d8a668b485784b1f653b51695f82980278276d44827d822987d189c2df · Zeichen 69471–72847 im Abschnitt
Wechselwirkungen · Aptivus
Aptivus 250 mg soft capsules · Abschnitt 4.5 · PDF-Seite 15–16
HOS-114832 · Präparat HOS-094169
15
Inhibition of CYP 3A4 by
tipranavir/r
HMG CoA reductase inhibitors
Atorvastatin 10 mg QD Atorvastatin Cmax ↑ 8.6 fold Co-administration of atorvastatin
Atorvastatin AUC ↑ 9.4 fold and Aptivus, co-administered
Atorvastatin Cmin ↑ 5.2 fold with low dose ritonavir, is not
recommended. Other HMG-CoA
Tipranavir ↔ reductase inhibitors should be
considered such as pravastatin,
Inhibition of CYP 3A4 by fluvastatin or rosuvastatin (See
tipranavir/r also section 4.4 and rosuvastatin
and pravastatin
recommendations). In cases
where co-administration is
necessary, the dose of 10 mg
atorvastatin daily should not be
exceeded. It is recommended to
start with the lowest dose and
careful clinical monitoring is
necessary (see section 4.4).
Rosuvastatin 10 mg QD Rosuvastatin Cmax ↑ 123% Co-administration of Aptivus, co-
Rosuvastatin AUC ↑ 37% administered with low dose
Rosuvastatin Cmin ↑ 6% ritonavir, and rosuvastatin should
be initiated with the lowest dose
Tipranavir ↔ (5 mg/day) of rosuvastatin,
titrated to treatment response, and
Mechanism unknown. accompanied with careful clinical
monitoring for rosuvastatin
associated symptoms as
described in the label of
rosuvastatin.
Pravastatin Based on similarities in the Co-administration of Aptivus, co-
No interaction study elimination between pravastatin administered with low dose
performed and rosuvastatin, TPV/r could ritonavir, and pravastatin should
increase the plasma levels of be initiated with the lowest dose
pravastatin. (10 mg/day) of pravastatin,
titrated to treatment response, and
Mechanism unknown. accompanied with careful clinical
monitoring for pravastatin
associated symptoms as
described in the label of
pravastatin.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atorvastatin (HOS-086304) rosuvastatin (HOS-086307) fluvastatin (HOS-086305) ritonavir (HOS-084521) pravastatin (HOS-086306)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-23T09:35:00Z · SHA-256 1c396190f98e89933229f2261b0e436bd43dac9c1de8e2dacaa36a755dc06dce · Passage 74f0f6a876d317957363e31e1c33f99584b8a000435d6c65678be0fe9ff9b411 · Zeichen 30010–33650 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 100 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 20–21
HOS-116410 · Präparat HOS-094447
20
ENDOTHELIN RECEPTOR ANTAGONISTS
Bosentan Not studied. Concomitant use of bosentan When administered concomitantly
and boosted PREZISTA may increase with PREZISTA and low dose
plasma concentrations of bosentan. ritonavir, the patient’s tolerability
of bosentan should be monitored.
Bosentan is expected to decrease plasma
concentrations of darunavir and/or its Co-administration of PREZISTA
pharmacoenhancer. co-administered with cobicistat
(CYP3A induction) and bosentan is not recommended.
HEPATITIS C VIRUS (HCV) DIRECT-ACTING ANTIVIRALS
NS3-4A protease inhibitors
Elbasvir/grazoprevir Boosted PREZISTA may increase the Concomitant use of boosted
exposure to grazoprevir. PREZISTA and
(CYP3A and OATP1B inhibition) elbasvir/grazoprevir is
contraindicated (see section 4.3).
Glecaprevir/pibrentasvir Based on theoretical considerations It is not recommended to
boosted PREZISTA may increase the co-administer boosted PREZISTA
exposure to glecaprevir and pibrentasvir. with glecaprevir/pibrentasvir.
(P-gp, BCRP and/or OATP1B1/3
inhibition)
HERBAL PRODUCTS
St John's Wort Not studied. St John’s Wort is expected Boosted PREZISTA must not be
(Hypericum perforatum) to decrease the plasma concentrations of used concomitantly with products
darunavir or its pharmacoenhancers. containing St John’s Wort
(CYP450 induction) (Hypericum perforatum) (see
section 4.3). If a patient is already
taking St John’s Wort, stop
St John’s Wort and if possible
check viral levels. Darunavir
exposure (and also ritonavir
exposure) may increase on
stopping St John’s Wort. The
inducing effect may persist for at
least 2 weeks after cessation of
treatment with St John’s Wort.
HMG CO-A REDUCTASE INHIBITORS
Lovastatin Not studied. Lovastatin and simvastatin Increased plasma concentrations of
Simvastatin are expected to have markedly increased lovastatin or simvastatin may
plasma concentrations when cause myopathy, including
co-administered with boosted rhabdomyolysis. Concomitant use
PREZISTA. of boosted PREZISTA with
(CYP3A inhibition) lovastatin and simvastatin is
therefore contraindicated (see
section 4.3).
Atorvastatin atorvastatin AUC ↑ 3-4 fold When administration of
10 mg once daily atorvastatin Cmin ↑ ≈5.5-10 fold atorvastatin and boosted
atorvastatin Cmax ↑ ≈2 fold PREZISTA is desired, it is
#
darunavir/ritonavir recommended to start with an
atorvastatin dose of 10 mg once
atorvastatin AUC ↑ 290% Ω daily. A gradual dose increase of
atorvastatin may be tailored to the
atorvastatin Cmax ↑ 319% Ω
clinical response.
atorvastatin Cmin ND Ω
Ω
with darunavir/cobicistat 800/150 mg
Pravastatin pravastatin AUC ↑ 81%¶ When administration of pravastatin
40 mg single dose pravastatin Cmin ND and boosted PREZISTA is
pravastatin Cmax ↑ 63% required, it is recommended to
¶
an up to five-fold increase was seen in a start with the lowest possible dose
limited subset of subjects of pravastatin and titrate up to the
desired clinical effect while
monitoring for safety.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): elbasvir (HOS-108814) protease (HOS-085623) lovastatin (HOS-086157) atorvastatin (HOS-086304) pibrentasvir (HOS-086298) cobicistat (HOS-088111) simvastatin (HOS-086158) glecaprevir (HOS-086297) hepatitis C virus (HOS-108813) grazoprevir (HOS-108815) ritonavir (HOS-084521) bosentan (HOS-086291) pravastatin (HOS-086306)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 6c740a1d89386aee87cf1f30365ea4ce6beb0a0dc719c309b037ce4e6094f9e7 · Zeichen 57628–63489 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 62–63
HOS-116528 · Präparat HOS-094447
62
ENDOTHELIN RECEPTOR ANTAGONISTS
Bosentan Not studied. Concomitant use of bosentan When administered concomitantly
and PREZISTA co-administered with with PREZISTA and low dose
low dose ritonavir may increase plasma ritonavir, the patient’s tolerability
concentrations of bosentan. of bosentan should be monitored.
Bosentan is expected to decrease plasma
concentrations of darunavir and/or its
pharmacoenhancer.
(CYP3A induction)
HEPATITIS C VIRUS (HCV) DIRECT-ACTING ANTIVIRALS
NS3-4A protease inhibitors
Elbasvir/grazoprevir PREZISTA with low dose ritonavir may Concomitant use of PREZISTA
increase the exposure to grazoprevir. with low dose ritonavir and
(CYP3A and OATP1B inhibition) elbasvir/grazoprevir is
contraindicated (see section 4.3).
Glecaprevir/pibrentasvir Based on theoretical considerations It is not recommended to
boosted PREZISTA may increase the co-administer boosted PREZISTA
exposure to glecaprevir and pibrentasvir. with glecaprevir/pibrentasvir.
(P-gp, BCRP and/or OATP1B1/3
inhibition)
HERBAL PRODUCTS
St John's Wort Not studied. St John’s Wort is expected PREZISTA co-administered with
(Hypericum perforatum) to decrease the plasma concentrations of low dose ritonavir must not be
darunavir and ritonavir. used concomitantly with products
(CYP450 induction) containing St John’s Wort
(Hypericum perforatum) (see
section 4.3). If a patient is already
taking St John’s Wort, stop
St John’s Wort and if possible
check viral levels. Darunavir
exposure (and also ritonavir
exposure) may increase on
stopping St John’s Wort. The
inducing effect may persist for at
least 2 weeks after cessation of
treatment with St John’s Wort.
HMG CO-A REDUCTASE INHIBITORS
Lovastatin Not studied. Lovastatin and simvastatin Increased plasma concentrations of
Simvastatin are expected to have markedly increased lovastatin or simvastatin may
plasma concentrations when cause myopathy, including
co-administered with rhabdomyolysis. Concomitant use
PREZISTAco-administered with low of PREZISTA co-administered
dose ritonavir. with low dose ritonavir with
(CYP3A inhibition) lovastatin and simvastatin is
therefore contraindicated (see
section 4.3).
Atorvastatin atorvastatin AUC ↑ 3-4 fold When administration of
10 mg once daily atorvastatin Cmin ↑ ≈5.5-10 fold atorvastatin and PREZISTA
atorvastatin Cmax ↑ ≈2 fold co-administered with low dose
#
darunavir/ritonavir ritonavir is desired, it is
recommended to start with an
atorvastatin dose of 10 mg once
daily. A gradual dose increase of
atorvastatin may be tailored to the
clinical response.
Pravastatin pravastatin AUC ↑ 81%¶ When administration of pravastatin
40 mg single dose pravastatin Cmin ND and PREZISTA co-administered
pravastatin Cmax ↑ 63% with low dose ritonavir is required,
¶
an up to five-fold increase was seen in a it is recommended to start with the
limited subset of subjects lowest possible dose of pravastatin
and titrate up to the desired clinical
effect while monitoring for safety.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): elbasvir (HOS-108814) protease (HOS-085623) lovastatin (HOS-086157) atorvastatin (HOS-086304) pibrentasvir (HOS-086298) simvastatin (HOS-086158) glecaprevir (HOS-086297) hepatitis C virus (HOS-108813) grazoprevir (HOS-108815) ritonavir (HOS-084521) bosentan (HOS-086291) pravastatin (HOS-086306)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage f0e95b466409a0cf2f8a9197f2461639fabe461c2c18b467893f52ceb3fe5916 · Zeichen 48435–54296 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 400 mg film-coated tablets PREZISTA 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 102–103
HOS-116618 · Präparat HOS-094447
102
ENDOTHELIN RECEPTOR ANTAGONISTS
Bosentan Not studied. Concomitant use of bosentan When administered concomitantly
and boosted PREZISTA may increase with PREZISTA and low dose
plasma concentrations of bosentan. ritonavir, the patient’s tolerability
Bosentan is expected to decrease plasma of bosentan should be monitored.
concentrations of darunavir and/or its
pharmacoenhancer. Co-administration of PREZISTA
(CYP3A induction) co-administered with cobicistat
and bosentan is not recommended.
HEPATITIS C VIRUS (HCV) DIRECT-ACTING ANTIVIRALS
NS3-4A protease inhibitors
Elbasvir/grazoprevir Boosted PREZISTA may increase the Concomitant use of boosted
exposure to grazoprevir. PREZISTA and
(CYP3A and OATP1B inhibition) elbasvir/grazoprevir is
contraindicated (see section 4.3).
Glecaprevir/pibrentasvir Based on theoretical considerations It is not recommended to
boosted PREZISTA may increase the co-administer boosted PREZISTA
exposure to glecaprevir and pibrentasvir. with glecaprevir/pibrentasvir.
(P-gp, BCRP and/or OATP1B1/3
inhibition)
HERBAL PRODUCTS
St John's Wort Not studied. St John’s Wort is expected Boosted PREZISTA must not be
(Hypericum perforatum) to decrease the plasma concentrations of used concomitantly with products
darunavir or its pharmacoenhancers. containing St John’s Wort
(CYP450 induction) (Hypericum perforatum) (see
section 4.3). If a patient is already
taking St John’s Wort, stop
St John’s Wort and if possible
check viral levels. Darunavir
exposure (and also ritonavir
exposure) may increase on
stopping St John’s Wort. The
inducing effect may persist for at
least 2 weeks after cessation of
treatment with St John’s Wort.
HMG CO-A REDUCTASE INHIBITORS
Lovastatin Not studied. Lovastatin and simvastatin Increased plasma concentrations of
Simvastatin are expected to have markedly increased lovastatin or simvastatin may
plasma concentrations when cause myopathy, including
co-administered with boosted rhabdomyolysis. Concomitant use
PREZISTA. of boosted PREZISTA with
(CYP3A inhibition) lovastatin and simvastatin is
therefore contraindicated (see
section 4.3).
Atorvastatin atorvastatin AUC ↑ 3-4 fold When administration of
10 mg once daily atorvastatin Cmin ↑ ≈5.5-10 fold atorvastatin and boosted
atorvastatin Cmax ↑ ≈2 fold PREZISTA is desired, it is
#
darunavir/ritonavir recommended to start with an
atorvastatin dose of 10 mg once
atorvastatin AUC ↑ 290% Ω daily. A gradual dose increase of
atorvastatin Cmax ↑ 319% Ω atorvastatin may be tailored to the
clinical response.
atorvastatin Cmin ND Ω
Ω
with darunavir/cobicistat 800/150 mg
Pravastatin pravastatin AUC ↑ 81%¶ When administration of pravastatin
40 mg single dose pravastatin Cmin ND and boosted PREZISTA is
pravastatin Cmax ↑ 63% required, it is recommended to
¶
an up to five-fold increase was seen in a start with the lowest possible dose
limited subset of subjects of pravastatin and titrate up to the
desired clinical effect while
monitoring for safety.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): elbasvir (HOS-108814) protease (HOS-085623) lovastatin (HOS-086157) atorvastatin (HOS-086304) pibrentasvir (HOS-086298) cobicistat (HOS-088111) simvastatin (HOS-086158) glecaprevir (HOS-086297) hepatitis C virus (HOS-108813) grazoprevir (HOS-108815) ritonavir (HOS-084521) bosentan (HOS-086291) pravastatin (HOS-086306)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage bf054a2c5f8c6d1a5be5b88714b31789a51a1dde2eabf2bbfe2ccb65fdbce96b · Zeichen 57100–62897 im Abschnitt
Wechselwirkungen · Intelence
INTELENCE 25 mg tablets INTELENCE 100 mg tablets INTELENCE 200 mg tablets · Abschnitt 4.5 · PDF-Seite 12–13
HOS-119741 · Präparat HOS-095005
12
OESTROGEN-BASED CONTRACEPTIVES
Ethinylestradiol ethinylestradiol The combination of
0.035 mg once daily AUC ↑ 1.22 (1.13-1.31) oestrogen- and/or
Norethindrone Cmin ↔ 1.09 (1.01-1.18) progesterone-based
1 mg once daily Cmax ↑ 1.33 (1.21-1.46) contraceptives and
norethindrone INTELENCE can be used
AUC ↔ 0.95 (0.90-0.99) without dose adjustment.
Cmin ↓ 0.78 (0.68-0.90)
Cmax ↔ 1.05 (0.98-1.12)
etravirine
AUC ↔a
Cmin ↔a
Cmax ↔a
HEPATITIS C VIRUS (HCV) DIRECT-ACTING ANTIVIRALS
Ribavirin Not studied, but no interaction expected based The combination of
on the renal elimination pathway of ribavirin. INTELENCE and ribavirin
can be used without dose
adjustments.
Daclatasvir Not studied. Co-administration of etravirine Co-administration of
with daclatasvir may decrease daclatasvir INTELENCE and daclatasvir
concentrations. is not recommended.
Elbasvir/grazoprevir Not studied. Co-administration of etravirine Co-administration is
with elbasvir/grazoprevir may decrease elbasvir contraindicated (see
and grazoprevir concentrations, leading to section 4.3).
reduced therapeutic effect of
elbasvir/grazoprevir.
HERBAL PRODUCTS
St John’s wort Not studied. St John’s wort is expected to Combination not
(Hypericum perforatum)
decrease the plasma concentrations of recommended.
etravirine.
HMG CO-A REDUCTASE INHIBITORS
Atorvastatin atorvastatin The combination of
40 mg once daily AUC ↓ 0.63 (0.58-0.68) INTELENCE and
Cmin ND atorvastatin can be given
Cmax ↑ 1.04 (0.84-1.30) without any dose
2-OH-atorvastatin adjustments, however, the
AUC ↑ 1.27 (1.19-1.36) dose of atorvastatin may
Cmin ND need to be altered based on
Cmax ↑ 1.76 (1.60-1.94) clinical response.
etravirine
AUC ↔ 1.02 (0.97-1.07)
Cmin ↔ 1.10 (1.02-1.19)
Cmax ↔ 0.97 (0.93-1.02)
Fluvastatin Not studied. No interaction between pravastatin Dose adjustments for these
Lovastatin and etravirine is expected. HMG Co-A reductase
Pravastatin Lovastatin, rosuvastatin and simvastatin are inhibitors may be necessary.
Rosuvastatin CYP3A4 substrates and co-administration with
Simvastatin etravirine may result in lower plasma
concentrations of the HMG Co-A reductase
inhibitor. Fluvastatin, and rosuvastatin are
metabolised by CYP2C9 and co-administration
with etravirine may result in higher plasma
concentrations of the HMG Co-A reductase
inhibitor.
H2-RECEPTOR ANTAGONISTS
Ranitidine etravirine INTELENCE can be
150 mg twice daily AUC ↓ 0.86 (0.76-0.97) co-administered with
Cmin ND H2-receptor antagonists
Cmax ↓ 0.94 (0.75-1.17) without dose adjustments.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): elbasvir (HOS-108814) daclatasvir (HOS-119742) lovastatin (HOS-086157) atorvastatin (HOS-086304) simvastatin (HOS-086158) rosuvastatin (HOS-086307) fluvastatin (HOS-086305) hepatitis C virus (HOS-108813) ribavirin (HOS-088127) grazoprevir (HOS-108815) ranitidine (HOS-085660) norethindrone (HOS-088136) pravastatin (HOS-086306)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-08-13T16:37:00Z · SHA-256 b6b2c3fd3d600c0f1fd17ddc8f6c1da50bcb8b2181089113d0397c5ec46864c4 · Passage b4ae62f3b56de12cf8406dcb55d38bc3538cd806a08b537965c6bb7ead0cc339 · Zeichen 24913–29265 im Abschnitt
Wechselwirkungen · Revolade
Revolade 12.5 mg film-coated tablets Revolade 25 mg film-coated tablets Revolade 50 mg film-coated tablets Revolade 75 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 12
HOS-122059 · Präparat HOS-095473
Administration of eltrombopag 75 mg once daily for 5 days with a single 10 mg dose of the OATP1B1
and BCRP substrate rosuvastatin to 39 healthy adult subjects increased plasma rosuvastatin Cmax 103%
(90% confidence interval [CI]: 82%, 126%) and AUC0- 55% (90% CI: 42%, 69%). Interactions are
also expected with other HMG-CoA reductase inhibitors, including atorvastatin, fluvastatin, lovastatin,
pravastatin and simvastatin. When co-administered with eltrombopag, a reduced dose of statins should
be considered and careful monitoring for statin adverse reactions should be undertaken (see
section 5.2).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lovastatin (HOS-086157) atorvastatin (HOS-086304) simvastatin (HOS-086158) rosuvastatin (HOS-086307) fluvastatin (HOS-086305) pravastatin (HOS-086306)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-26T10:21:00Z · SHA-256 3912609780c75b6cf657bad81a36f25e9a4985d64364fb3ab11f095445db8751 · Passage 0cc6386bb923481f82383194897ccaa3e68fec9b77243bccf999c6446b94ecd2 · Zeichen 82–685 im Abschnitt
Wechselwirkungen · Revolade
Revolade 25 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 52
HOS-122155 · Präparat HOS-095473
Administration of eltrombopag 75 mg once daily for 5 days with a single 10 mg dose of the OATP1B1
and BCRP substrate rosuvastatin to 39 healthy adult subjects increased plasma rosuvastatin Cmax 103%
(90% confidence interval [CI]: 82%, 126%) and AUC0- 55% (90% CI: 42%, 69%). Interactions are
also expected with other HMG-CoA reductase inhibitors, including atorvastatin, fluvastatin, lovastatin,
pravastatin and simvastatin. When co-administered with eltrombopag, a reduced dose of statins should
be considered and careful monitoring for statin adverse reactions should be undertaken (see
section 5.2).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lovastatin (HOS-086157) atorvastatin (HOS-086304) simvastatin (HOS-086158) rosuvastatin (HOS-086307) fluvastatin (HOS-086305) pravastatin (HOS-086306)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-26T10:21:00Z · SHA-256 3912609780c75b6cf657bad81a36f25e9a4985d64364fb3ab11f095445db8751 · Passage 0cc6386bb923481f82383194897ccaa3e68fec9b77243bccf999c6446b94ecd2 · Zeichen 82–685 im Abschnitt
Wechselwirkungen · Leflunomide Zentiva (previously Leflunomide Winthrop)
Leflunomide Zentiva 10 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9
HOS-122371 · Präparat HOS-095511
Effect on BCRP (Breast Cancer Resistance Protein) and /or organic anion transporting polypeptide B1
and B3 (OATP1B1/B3) substrates
There was an increase in mean rosuvastatin Cmax and AUC (2.65- and 2.51-fold, respectively),
following repeated doses of A771726. However, there was no apparent impact of this increase in
plasma rosuvastatin exposure on the HMG-CoA reductase activity. If used together, the dose of
rosuvastatin should not exceed 10 mg once daily. For other substrates of BCRP (e.g., methotrexate,
topotecan, sulfasalazine, daunorubicin, doxorubicin) and the OATP family especially HMG-CoA
reductase inhibitors (e.g., simvastatin, atorvastatin, pravastatin, methotrexate, nateglinide, repaglinide,
rifampicin) concomitant administration should also be undertaken with caution. Patients should be
closely monitored for signs and symptoms of excessive exposure to the medicinal products and
reduction of the dose of these medicinal products should be considered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): daunorubicin (HOS-089674) sulfasalazine (HOS-089673) atorvastatin (HOS-086304) simvastatin (HOS-086158) rosuvastatin (HOS-086307) nateglinide (HOS-089675) topotecan (HOS-086047) doxorubicin (HOS-084538) repaglinide (HOS-086935) pravastatin (HOS-086306) methotrexate (HOS-087522)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-22T17:27:00Z · SHA-256 bed6a472e84572491a61af1acb52b0f05e60157fe2f2f53c93e4e488c7c80e1b · Passage c722438444f15a50fbfd7f4174841441ed2887a9c672757af10708a7ffdb036d · Zeichen 5507–6481 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.